Nivolumab for adults with Hodgkin's lymphoma (a rapid review using the software RobotReviewer).
CONCLUSIONS: To date, data on OS, quality of life, PFS, response rate, or short- and long-term AEs are available from small uncontrolled trials only. The three trials included heavily pretreated participants, which had previously undergone regimens of BV or ASCT. For these participants, median OS was not reached after follow-up times of at least 16 months (more than 50% of participants with a limited life expectancy were alive at this timepoint). Only one cohort out of three only reported quality of life, with limited follow-up data so that meaningful conclusions were not possible. Serious adverse events occurred rarely. Currently, data are too sparse to make a clear statement on nivolumab for people with relapsed or refractory HL except for heavily pretreated people, which had previously undergone regimens of BV or ASCT. When interpreting these results, it is important to consider that proper RCTs should confirm these findings.As there are 14 ongoing trials evaluating nivolumab, of which two are RCTs, it is possible that an update of this review will be published in the near future and that this update will show different results to those reported here.
PMID: 30001476 [PubMed - as supplied by publisher]
Source: Cochrane Database of Systematic Reviews - Category: General Medicine Authors: Goldkuhle M, Dimaki M, Gartlehner G, Monsef I, Dahm P, Glossmann JP, Engert A, von Tresckow B, Skoetz N Tags: Cochrane Database Syst Rev Source Type: research
More News: Cancer | Cancer & Oncology | Carcinoma | Chemotherapy | Conferences | Databases & Libraries | Diarrhoea | General Medicine | Hepatocellular Carcinoma | Hodgkin's Disease | Kidney Cancer | Liver | Liver Cancer | Liver Transplant | Lung Cancer | Lung Transplant | Lymphoma | Melanoma | Non-Small Cell Lung Cancer | Renal Cell Carcinoma | Skin Cancer | Stem Cell Therapy | Stem Cells | Study | Transplants | Urology & Nephrology